HENDERSON MICHAEL THOMAS (Chief Executive Officer) sold 1.7% of their position (20K shares) of APOGEE THERAPEUTICS, INC. on the open market
Open‑market sale worth $1.50M — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 3/13/2026ACC: 0001104659-26-027802
DirectorOfficer· Chief Executive Officer
Since Feb 2026
-20K
Net shares
Net seller
$1.50M
Total sold
3
Open market trades
0B · 3S
3
Total transactions
20K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−8.36K
Price / share
$74.29
Trade value
$621.29K
% of position
0.7%
3/11/2026
1.17M→1.16M
Common Stock
Direct
Shares
−8.22K
Price / share
$74.83
Trade value
$615.03K
% of position
0.7%
3/11/2026
1.16M→1.16M
Common Stock
Direct
Shares
−3.42K
Price / share
$75.86
Trade value
$259.29K
% of position
0.3%
3/11/2026
1.16M→1.15M
Total
Net shares
−20K
Net value
-$1.50M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/11/2026 | S · Sale | −8.36K | $74.29 | $621.29K | 0.7% | 1.17M | 1.16M |
| Common Stock Direct | 3/11/2026 | S · Sale | −8.22K | $74.83 | $615.03K | 0.7% | 1.16M | 1.16M |
| Common Stock Direct | 3/11/2026 | S · Sale | −3.42K | $75.86 | $259.29K | 0.3% | 1.16M | 1.15M |
| Total | −20K | -$1.50M | ||||||
Derivative Transactions0
No derivative transactions reported